In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A compound ~~having the~~ of formula (**I**)



(**I**)

wherein

X is N ~~or CH~~;

Y is ~~NR_2CH_2~~, CH_2NR_2, NR_2CO, $CONR_2$, NR_2SO_2 or NR_2CONR_2

wherein R_2 is H or C_1-C_6 alkyl;

R_1 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

R_3 is ~~C_1-C_6 alkyl, C_3-C_6 cycloalkyl or $(CH_2)_n$-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which~~ $(CH_2)_n$-phenyl, wherein the phenyl may be mono- or di-substituted with R_4 and/or R_5;

wherein R_4 is selected from

a) H,

b) C_1-C_6 alkyl,

c) C_3-C_6 cycloalkyl,

d) halogen,

e) CN,

f) CF_3,

g) OH,

h) C_1-C_6 alkoxy,

i) NR_6R_7,

j) OCF_3,

k) SO_3CH_3,

l) SO_3CF_3,

m) $SO_2NR_6R_7$,

n) phenyl,

o) phenyl-C_1-C_6 alkyl,

p) phenoxy,

q) C_1-C_6 alkylphenyl,

r) an optionally substituted 5-, 6- or 7-membered heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO_2, wherein when the heterocyclic ring is 5- or 6-membered and contains one heteroatom, the heteroatom is not N and when the heterocyclic ring is 5- or 6-membered and contains two heteroatoms, the heteroatoms are not both N and wherein the substituent(s) is(are) selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, phenyl-C_1-C_6 alkyl, $(CH_2)_mOR_9$ wherein m is 2-6 and R_9 is H,

C_1-C_6 alkyl, C_3-C_6 cycloalkyl or phenyl-C_1-C_6 alkyl, and COR_8,

s) an optionally substituted 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected from N, O and S, wherein when the heteroaromatic ring contains one heteroatom, the heteroatom is not N and when the heteroaromatic ring contains two heteroatoms, the heteratoms are not both N and wherein the substituent(s) is(are) selected from C_1-C_6 alkyl, C_3C_6 cycloalkyl and phenyl-C_1-C_6 alkyl, ~~or~~ and

t) COR_8;

wherein R_6 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl; R_7 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl; and R_8 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, CF_3, NR_6R_7, or phenyl~~, a heteroaromatic ring containing one or two heteroatoms selected from N, O and S or a heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO_2~~;

R_5 is selected from H, OH, CF_3, OCF_3, halogen, C_1-C_6 alkyl ~~or~~ and C_1-C_6 alkoxy;

and n is 0-4;

~~as~~ wherein the compound is an (*R*)-enantiomer~~s~~, an (*S*)-

enantiomers, or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.

2. (currently amended) ~~A~~ The compound according to claim 1 wherein Y is NR_2CO or $CONR_2$.

3. (cancelled)

4. (currently amended) ~~A~~ The compound according to ~~any one of claims 1-3~~ claim 1, wherein R_1 is H or C_1-C_6 alkyl.

5. (cancelled)

6. (currently amended) ~~A~~ The compound according to ~~any one of claims 1-4~~ claim 1, wherein ~~R_3 is $(CH_2)_n$-aryl which~~ the phenyl ring of substituent R_3 is substituted with R_4, and R_4 ~~which~~ is an optionally substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N, O and ~~S,~~ S; or COR_8.

7. (currently amended) ~~A~~ The compound according to ~~any one of claims 5 and 6~~ claim 6, wherein n is 0.

8. (currently amended) ~~A~~ The compound according to claim 6 wherein R_8 is NR_6R_7 ~~or a heterocyclic ring containing two heteroatoms selected from N and O~~.

9. (currently amended) ~~A~~ The compound according to ~~any one of claims 1- 8~~ claim 1, wherein ~~X is N and~~ Y is NR_2CO.

10. (currently amended) ~~A~~ The compound according to claim ~~9~~ 1 wherein ~~X is N,~~ Y is NR_2CO and R_4 is morpholino or COR_8.

11. (cancelled)

12. (currently amended) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of ~~any one of claims 1-11~~ claim 1 as an enantiomer or racemate, in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally in association with diluents, excipients or inert carriers.

13. (currently amended) A ~~pharmaceutical formulation according to claim 12 for use in~~ method for the treatment of 5-hydroxytryptamine-mediated disorders, comprising administering to a patient in need of such treatment a

therapeutically effective amount of the pharmaceutical formulation of claim 12.

14-24. (cancelled)

25. (currently amended) A method for the treatment of disorders in the central nervous system and/or urinary incontinence or vasospasm or for inhibiting tumor growth ~~control of tumors by~~ comprising administering to a mammal ~~including man~~ in need of such ~~a~~ treatment a therapeutically effective amount of a compound defined in ~~any of claims 1-11~~ claim 1.

26. (currently amended) ~~A~~ The method according to claim 25 ~~for the treatment of~~ wherein the disorders of the central nervous system are mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.

27. (currently amended) A method for the treatment of 5-hydroxytryptamine mediated disorders ~~by~~ comprising administering to a mammal ~~including man~~ in need of such ~~a~~

treatment a therapeutically effective amount of a compound defined in ~~any of claims 1-11~~ claim 1.

28. (currently amended) A method ~~according to claim 27 wherein the compound according to any one of claims 1-11 is used as a~~ for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system which require treatment with an h5-HT_{1B} antagonist, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

29. (currently amended) A process for the preparation of the compound of formula I according to claim 1 ~~by~~, comprising:

A(i)

acylation, in the case ~~when~~ wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, Y is NR_2CO, R_2 is hydrogen and X and R_3 are as defined ~~in general formula I~~ in claim 1, of a compound of formula **A**,



(A) (I)

with an activated carboxylic acid R_3-$COLg_1$ wherein Lg_1 is a leaving group; or ~~by using~~ with a carboxylic acid R_3-COOH ~~with~~ and an activating reagent;

A(ii)

acylation, in the case ~~when~~ wherein R_1 is hydrogen, Y is NR_2CO, R_2 is hydrogen, R_c is a protecting group and X and R_3 are as defined ~~in general formula I~~ in claim 1, of a compound of formula **B**



(B) (I)

with an activated carboxylic acid R_3-$COLg_1$ wherein Lg_1 is a leaving group; or ~~by using~~ with a carboxylic acid R_3-COOH ~~with~~ and an activating reagent, ~~followed by the removal of~~ and removing the protecting group R_c;

A(iii)

debenzylation, in the case ~~when~~ wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, X and R_2 are as defined in ~~general formula I above~~ claim 1 and R_9 below is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, $(CH_2)_mOH$ wherein m is 2-6, or COR_8, of a compound of formula **Ia**, followed by a) hydrogenation, b)

alkylation, c) alkylation and removal of a protecting group or d) acylation;



(Ia) (I)

B(i)

reacting ,in the case ~~when~~ wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, Y is $CONR_2$, and X, R_2 and R_3 are as defined in ~~general formula I above~~ claim 1, an activated carboxylic

acid of a compound of formula **C**;



(C) **(I)**

with an aniline or an amine HNR_2R_3; or

B(ii)

reacting, in the case ~~when~~ wherein R_1 is hydrogen, Y is NR_2CO, R_C is a protecting group and X, R_2 and R_3 are as defined in ~~general formula I above~~ claim 1, an activated carboxylic acid of a compound of formula **D**



(D) **(I)**

with an aniline or an amine HNR_2R_3, ~~followed by removal of~~ and removing the protecting group ~~R_C-~~R_C; or

C

~~reaction~~ reacting, in the case ~~when~~ wherein R_1 is C_1-C_6 alkyl

or C_3-C_6 cycloalkyl, Y is NR_2CONR_2, R_2 is hydrogen and X and R_3 are as defined in ~~general formula I above~~ claim 1, a compound of formula **A**,



(A) **(I)**

with a suitable azide in the presence of a carboxylic acid, R_3COOH.

30. (currently amended) A compound ~~having~~ of the formula.



wherein

X=N ~~or CH~~;

Z=NH_2 or COOH; and

R_1 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl.